Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Coffee Microcaps (October 2020)
17 slides from Nova Eye Medical's conference presentation, Oct 30, 2020
Slide 1: Presentation to Coffee Microcaps
1 PRESENTATION TO COFFEE MICROCAPS (ASX:EYE) 30 October 2020
Slide 2: Disclaimer
2 DISCLAIMER This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any
Slide 3: Our Business
3 OUR BUSINESS Following the divestment of the capital equipment business and the payment of a $61m distribution to shareholders, the Company is now focusing on the fastest growing segment of the ophthalmic market, consumable surgical devices for glaucoma disease management. § Our primary focus is t
Slide 4: Our Current Technologies
4 OUR CURRENT TECHNOLOGIES iTRACK™ MOLTENO3® 2RT® FOR GLAUCOMA FOR GLAUCOMA FOR EARLY AMD Our proprietary iTrack ™ MIGS technology Acquired from world-leader Molteno Our proprietary 2RT ® nanosecond laser is redefining the treatment of mild- Ophthalmic Ltd, the portfolio of Molteno therapy is a worl
Slide 5: Our Primary Focus Is a Pipeline of Glaucoma Products
5 OUR PRIMARY FOCUS IS A PIPELINE OF GLAUCOMA PRODUCTS We are expanding our glaucoma treatment portfolio to address the cycle of the disease progression. . EARLY MODERATE SEVERE/LATE STAGE iTRACK™ iTRACK ™ MOLTENO3 ® OPPORTUNITIES AB-INTERNO OPPORTUNITIES AB-EXTERNO TUBESHUNT CANALOPLASTY FOR GROWTH
Slide 6: Global Offices
6 GLOBAL OFFICES Global staff = 50 people GERMANY USA Nova Eye Nova Eye, Inc Medical GmbH NEW ZEALAND Molteno Ophthalmic Ltd Headquarters USA German Sales iTrack™ Manufacturing Molteno Manufacturing iTrack™ R&D AUSTRALIA Molteno Quality iTrack™ Quality & Nova Eye Medical Ltd & Regulatory Regulatory
Slide 7: FY20 Company Snapshot (ASX:EYE)
7 FY20 COMPANY SNAPSHOT (ASX:EYE) Pro-Forma Pro-Forma Market Capitalisation1 Cash2 Enterprise Value3 Global Employees $46 million $26.5 million $16.5 million 50 FY20 Cash Outflow from Directors & Mgt. Own FY20 Revenue4 FY20 EBITDA5 Continuing Operations 14% $12.8 million -$5.8 million -$3.7 million
Slide 8: Profit & Loss Nova Eye Medical
8 PROFIT & LOSS NOVA EYE MEDICAL $000’s FY19 FY20 % Change § Worldwide iTrack unit volumes decreased 11% on pcp, revenues down 19%: COVID-19 impacts Revenue - iTrack 14,324 11,572 -19% - 2RT (early adopter) 1,816 1,197 § USA unit sales down 28%, OUS (excluding China) down 35% primarily due to 2H COV
Slide 9: Molteno Acquisition
9 MOLTENO ACQUISITION § Acquisition completed on 3 August 2020 for NZ$1.05 million (A$0.99 million) in cash, representing an acquisition multiple of 1.2x FY20 revenues 1 § The Molteno range offers significant product advantages but underpenetrates the market because of insufficient investment in cli
Slide 10: AlphaRET Pty Ltd is a wholly owned subsidiary of Nova Eye Medical
10 AlphaRET Pty Ltd is a wholly owned subsidiary of Nova Eye Medical (ASX:EYE) Commercial arm established in October 2020 to facilitate development of the Company’s proprietary 2RT® Project
Slide 11: 2RT Is Groundbreaking Nano Pulse Laser Therapy for AMD
11 2RT® IS GROUNDBREAKING NANO PULSE LASER THERAPY FOR AGE RELATED MACULAR DEGENERATION (AMD) • Current AMD therapy only treats the symptoms of the disease, and is only available for the late stage of the disease, using expensive AMD is the world’s pharmaceuticals delivered via invasive bi-monthly o
Slide 12: 2RT for Patients Before Late Stage Disease
12 2RT® FOR PATIENTS BEFORE LATE STAGE DISEASE Normal Vision Morbidity Health of retina & macula 2RT® slows AMD AMD progression progression by 77% without 2RT Defer late stage 2RT application of disease (CNV / GA) nano pulse laser Visual difficulty GA with vision loss, or CNV requiring Blindness ant
Slide 13: 2RT Clinical Study (LEAD) Demonstrated Reduction in Rate of Disease Progression
13 2RT® PHASE 2 CLINICAL STUDY (“LEAD”) DEMONSTRATED A REDUCTION IN THE RATE OF DISEASE PROGRESSION NOT ACHIEVED BY ANY OTHER THERAPY 2RT® significantly reduced rate of disease progression to late- stage AMD in patients 77% 77% reduced rate 4x Four-fold reduction in without reticular of progression
Slide 14: 2RT Can Meet a Substantial Unmet Need – iAMD
14 2RT® CAN MEET A SUBSTANTIAL UNMET NEED – iAMD Population with Early Remove patients with RPD, Estimated population and Intermediate AMD1 early AMD and nGA patients2 with Intermediate AMD (millions of people) (millions of people) (millions of people) USA 13.9 -8.6 5.3 Europe 21.6 -13.4 8.2 Other w
Slide 15: 2RT Status as of October 2020
15 2RT® STATUS AS OF OCTOBER 2020 § LEAD (Phase 2) Study post hoc analysis showed strong results over 3 year follow up § Expansion of 2RT® existing indication from FDA for use to include iAMD requires an additional pivotal study for registration § Solid progress with US FDA during the 2020 year via
Slide 16: Outlook
16 OUTLOOK Nova Eye Medical has a number of objectives for the 2021 financial year, which are shown below: 1. Investment into iTrack™ and Molteno3® in clinical market development in preparation for aggressive sales drive post COVID-19 2. Product development including next generation iTrack™ for depl
Slide 17: Contacts
17 CONTACTS COMPANY INVESTORS MEDIA Mr Tom Spurling Dr Tom Duthy Ms Kate Hunt Director Investor Relations and Head of Marketing W: +61 8 8362 0193 Corporate Development M: +61 404 080 679 E: tspurling@nova-eye.com M: +61 402 493 727 E: khunt@nova-eye.com E: tduthy@nova-eye.com